LB Pharmaceuticals Inc (LBRX): Total Assets
$312.93M
As of 2025-12-31
$361.69M
As of 2026-06-30
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $312.93M | +833.2% | 2026-03-26, Balance as of period end |
| 2024-12-31 | $33.53M | n/a | 2026-03-26, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| LB Pharmaceuticals Inc (LBRX) | 2025-12-31 | $312.93M | +833.2% |
| Atea Pharmaceuticals, Inc. (AVIR) | 2025-12-31 | $315.22M | -32.2% |
| ADC Therapeutics SA (ADCT) | 2025-12-31 | $323.15M | +0.4% |
| Omeros Corp (OMER) | 2025-12-31 | $325.63M | +17.5% |
| Sionna Therapeutics, Inc. (SION) | 2025-12-31 | $325.95M | +75.5% |
| Prothena Corp Public Ltd Co (PRTA) | 2025-12-31 | $326.80M | -40.3% |
| ARS Pharmaceuticals, Inc. (SPRY) | 2025-12-31 | $327.65M | -6.7% |
| Liquidia Corp (LQDA) | 2025-12-31 | $327.93M | +42.4% |
| Cartesian Therapeutics, Inc. (RNAC) | 2025-12-31 | $296.41M | -31.9% |
Compare LBRX, AVIR, ADCT, OMER side by side · Screen every company in Pharmaceutical Preparations ↗